checked for completion by RP-HPLC (system C). The crude
product was then dissolved in aq. TEAB and twice purified by RP-
HPLC (system D followed by system E). The product-containing
fractions were lyophilised to give the desired lysine conjugate,
which was rapidly desalted by ion-exchange chromatography (to
remove triethylammonium salts) and again lyophilised to give the
acid form of disulfonated monofluoro-Boc-L-lysine derivative 5.
Finally, a third RP-HPLC purification (system F) was performed
to remove the free-amino lysine derivative formed during the ion-
exchange chromatography through the premature cleavage of the
Boc protecting group. Finally, the desired product was obtained
as a white solid (2.8 mg, yield 7%). dH (300 MHz, DMSO-d6)
8.18 (m, 2H), 7.79 (t, J 7.9, 2H), 4.93–4.91 (m, 1H), 4.51–4.42
(m, 1H), 4.24 (t, J 8.6, 2H), 3.77 (t, J 7.4, 2H), 2.67–2.60 (m,
2H), 1.77–1.74 (m, 2H), 1.65–1.55 (m, 2H), 1.37 (s, 9H), 1.31–
1.24 (m, 2H); dF (282.5 MHz, DMSO-d6) -216.7 (m, –CH2F); MS
(ESI-): m/z 620.07 [M - H2O - H]- (cyclic enamine formation
occurred during the ionisation process), 638.07 [M - H]-, calcd
for C25FH38N3O11S2 639.19; HPLC (system C): tR = 15.3 and 15.9
min (four diastereomers, purity 98%); lmax (recorded during the
HPLC analysis)/nm 265.
with a 95% radiochemical purity. HPLC (system A): tR = 18.2 min
(two racemic diastereomers).
[18F]-Labelled dodecapeptide (9). Dodecapeptide and a large
excess of DIEA were put into a reaction vial and dry DMF
(100 mL) was added. Then, 1 mL of the CH3CN solution [18F]-
fluoropropanesultone 7 (vide supra) was added. The vial was put on
a hotplate and heated at 80 ◦C for 30 min. Thereafter, the reaction
was stopped and directly analysed by RP-HPLC (system A with
radioactivity detection). HPLC (system A): tR = 19.8 min (two
racemic diastereomers). The retention time difference between
the UV and radio traces (ca. 1 min) was caused by the serial
arrangement of the detectors.
Acknowledgements
Financial support from La Re´gion Haute-Normandie (for ac-
quiring HPLC instruments and peptide synthesizer), Institut Uni-
versitaire de France (IUF) and a Ph.D. grant from L’Association
Nationale de la Recherche et de la Technologie (ANRT)toThomas
Priem are greatly acknowledged. We thank Annick Leboisselier
(INSA de Rouen) for the determination of elemental analyses and
Ce´drik Massif (Ph.D., Bioorganic Team, Universite´ de Rouen) for
IR measurements.
Monofluoro-peptide conjugate (6)
Monofluoropropanesultone 4 (1.6 mg, 4.06 mmol, 1.6 equiv.) was
dissolved in dry DMF (0.6 mL) and a dodecapeptide (its sequence
is confidential and not disclosed within this article but it contains a
single reactive lysine residue, 5.0 mg, 2.6 mmol, 1 equiv.) previously
dissolved in dry DMF (0.6 mL) and DIEA (10 mL, 57.4 mmol,
15 equiv.) was added. The resulting reaction mixture was stirred
at rt for 8 h and checked for completion by RP-HPLC (system A).
The crude product was then dissolved with aq. TFA and purified
by RP-HPLC (system F). The product-containing fractions were
lyophilised to give the desired monofluoro-peptide conjugate as a
white solid (250 mg, yield 5%). MS (ESI+): m/z 925.40 [M - H2O
+ 2H]2+ (cyclic enamine formation occurred during the ionisation
process), 934.33 [M + 2H]2+, calcd for C79FH128N23O24S2 1865.89;
HPLC (system A): tR = 20.8 min (four diastereomers, purity 94%);
lmax (recorded during the HPLC analysis)/nm 266.
Notes and references
1 A. P. Schubiger, L. Lehmann and M. Friebe, PET Chemistry: The
Driving Force in Molecular Imaging, Springer, Berlin Heidelberg,
2007.
2 (a) S. M. Ametamey, M. Honer and P. A. Schubiger, Chem. Rev., 2008,
108, 1501; (b) S. L. Pimlott and A. Sutherland, Chem. Soc. Rev., 2011,
40, 149.
3 S. M. Okarvi, Eur. J. Nucl. Med., 2001, 28, 929.
4 H. J. Wester and M. Schottelius, in PET Chemistry: The Driving Force
in Molecular Imaging, ed. A. P. Schubiger, L. Lehmann and M. Friebe,
Springer, Berlin Heidelberg, 2007, vol. 62, p. 79 and references cited
therein.
5 (a) J. Becaud, L. Mu, M. Karramkam, P. A. Schubiger, S. M. Ametamey,
K. Graham, T. Stellfeld, L. Lehmann, S. Borkowski, D. Berndorff,
L. Dinkelborg, A. Srinivasan, R. Smits and B. Koksch, Bioconjugate
Chem., 2009, 20, 2254; (b) A. Hohne, L. Mu, M. Honer, P. A. Schubiger,
S. M. Ametamey, K. Graham, T. Stellfeld, S. Borkowski, D. Berndorff,
U. Klar, U. Voigtmann, J. E. Cyr, M. Friebe, L. Dinkelborg and A.
Srinivasan, Bioconjugate Chem., 2008, 19, 1871; (c) O. Jacobson, L.
Zhu, Y. Ma, I. D. Weiss, X. Sun, G. Niu, D. O. Kiesewetter and X.
Chen, Bioconjugate Chem., 2011, 22, 422; (d) L. Mu, A. Hohne, P. A.
Schubiger, S. M. Ametamey, K. Graham, J. E. Cyr, L. Dinkelborg, T.
Stellfeld, A. Srinivasan, U. Voigtmann and U. Klar, Angew. Chem., Int.
Ed., 2008, 47, 4922; (e) U. Roehn, J. Becaud, L. Mu, A. Srinivasan, T.
Stellfeld, A. Fitzner, K. Graham, L. Dinkelborg, A. P. Schubiger and
S. M. Ametamey, J. Fluorine Chem., 2009, 130, 902.
6 For selected examples, see: (a) B. De Bruin, B. Kuhnast, F. Hinnen,
L. Yaouancq, M. Amessou, L. Johannes, A. Samson, R. Boisgard, B.
Tavitian and F. Dolle, Bioconjugate Chem., 2005, 16, 406; (b) F. Wuest,
M. Berndt, R. Bergmann, J. van den Hoff and J. Pietzsch, Bioconjugate
Chem., 2008, 19, 1202; (c) I. Koslowsky, J. Mercer and F. Wuest, Org.
Biomol. Chem., 2010, 8, 4730.
7 P. Johnstro¨m, J. C. Clark, J. D. Pickard and A. P. Davenport, Nucl.
Med. Biol., 2008, 35, 725.
8 (a) M. Glaser and E. G. Robins, J. Labelled Compd. Radiopharm., 2009,
52, 407; (b) C. Mamat, T. Ramenda and F. R. Wuest, Mini-Rev. Org.
Chem., 2009, 6, 21; (c) T. L. Ross, Curr. Radiopharm., 2010, 3, 202; (d) C.
Waengler, R. Schirrmacher, P. Bartenstein and B. Waengler, Curr. Med.
Chem., 2010, 17, 1092.
9 For selected examples, see: (a) T. Ramenda, T. Kniess, R. Bergmann, J.
Steinbach and F. Wuest, Chem. Commun., 2009, 7521; (b) D. Thonon,
C. Kech, J. Paris, C. Lemaire and A. Luxen, Bioconjugate Chem., 2009,
Radiosyntheses
Mono-[18F]-fluoropropanesultone (7). Following delivery of
[18F]-fluoride to the synthesizer module, the radioactivity was
isolated on a QMA cartridge, allowing recovery of [18O]-H2O. The
[18F]-fluoride was eluted with a mixed solution of Kryptofix[K222]
(19.8 mg) in CH3CN (550 mL) and of K2CO3 (3.25 mg) in deionised
water (50 mL), and transferred to the reaction vial. After azeotropic
evaporation of water (3 ¥ CH3CN, 95 ◦C, with a stream of N2
gas), bis-propanesultone 3 (3.5 mg) in dry CH3CN (1 mL) was
added. The radiolabelling was conducted in the reaction vial at
100 ◦C over 20 min. After dilution in a large volume of deionised
water (40–50 mL), the reaction mixture was then loaded onto
a HLB cartridge. After washing of the reactor vial with a 3%
solution of CH3CN in deionised water (10 mL), the product was
finally eluted from the cartridge using a 17% solution of CH3CN
in deionised water (15 mL). Mono-[18F]-fluoropropanesultone 7
was obtained within 40 min with a moderate 25% decay-corrected
radiochemical yield (average value from n = 25 preparations) and
This journal is
The Royal Society of Chemistry 2012
Org. Biomol. Chem., 2012, 10, 1068–1078 | 1077
©